(Reuters) – Pfizer Inc (N:) is in talks to merge its off-patent drugs business with Mylan NV (O:) in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.
Mylan shareholders would receive a little more than 40% of the newly formed entity, with Pfizer shareholders receiving the remainder, the Journal said, adding Pfizer would also get about $12 billion in proceeds from a new sale of debt.
Pfizer and Mylan did not immediately respond to requests for comment.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.